May 15, 2019
Patient Study: LCA-10 And USH2
We are letting our community know about a patient experience study being conducted by Medicys Ltd., a medical research company that is looking for people with a confirmed diagnosis of Usher syndrome type 2A (USH2) or Leber congenital amaurosis 10 (LCA-10) to share their experiences living with a blinding eye disease.
At Fighting Blindness Canada (FBC), we support these sorts of patient experience studies because they provide extremely useful data points for developing treatments for blinding eye diseases. By understanding the lived experience of people with blinding eye diseases, organizations can better develop treatments that address the needs of the patient population.
The study involves a 15-minute questionnaire and a 60-minute interview. Participants will be asked about their first-hand experiences living with LCA-10 or USH2, including what led to the diagnosis, the challenges faced in living with the diagnosis, and the role that doctors have played in their journey. This study is also open to parents or caregivers of people living with LCA-10 or USH2.
Participants will receive a $80 honorarium for their time. All personal information will be kept strictly confidential in accordance with data protection laws, and conversations will be for research purposes only.
To learn more about this project and see if you might quality, please contact Alisha Hobson at 416.360.4200 x 235 or email email@example.com. This study closes on May 22.
Latest FBC News View All
A Message from the President and CEO For 45 years, the Foundation Fighting Blindness has raised and directed critical funding into sight-saving research for blinding eye diseases. From our earliest days as…Read More
This year, participants in Cycle for Sight events across the country set off on exciting routes through farmland, fields, and country lanes. As with any adventure, our cyclists occasionally came across the…Read More
Alongside our partners at the Canadian Retina Society, the Canadian Council of the Blind, and Novartis, we’re raising awareness about the signs and symptoms of age-related macular degeneration. Check out our PSA,…Read More
This month, the Inherited Retinal Dystrophies Consortium Operating for the Under-Represented for Novel Therapies and Services (IRD COUNTS) released a landmark study highlighting the personal costs of living with an inherited retinal…Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.